HRP20211561T1 - Modulacija aktivnosti komplementa - Google Patents

Modulacija aktivnosti komplementa Download PDF

Info

Publication number
HRP20211561T1
HRP20211561T1 HRP20211561TT HRP20211561T HRP20211561T1 HR P20211561 T1 HRP20211561 T1 HR P20211561T1 HR P20211561T T HRP20211561T T HR P20211561TT HR P20211561 T HRP20211561 T HR P20211561T HR P20211561 T1 HRP20211561 T1 HR P20211561T1
Authority
HR
Croatia
Prior art keywords
group
absent
polypeptide
acid
methyl
Prior art date
Application number
HRP20211561TT
Other languages
English (en)
Inventor
Michelle Denise HOARTY
Ketki Ashok DHAMNASKAR
Daniel Elbaum
Kristopher JOSEPHSON
Kelley Cronin LARSON
Zhong MA
Nathan Ezekiel Nims
Alonso RICARDO
Kathleen Seyb
Guo-Qing Tang
Douglas A. Treco
Zhaolin Wang
Ping Ye
Hong Zheng
Sarah Jacqueline PERLMUTTER
Robert Paul Hammer
Original Assignee
Ra Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ra Pharmaceuticals, Inc. filed Critical Ra Pharmaceuticals, Inc.
Publication of HRP20211561T1 publication Critical patent/HRP20211561T1/hr
Publication of HRP20211561T8 publication Critical patent/HRP20211561T8/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (15)

1. Polipeptid s formulom R1-Xaa0-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-R2, naznačen time što: (a) R1 je odabran iz skupine koju čine H, acetilna skupina, acilna skupina koja sadrži linearni ili razgranati, zasićeni ili nezasićeni lanac ugljikovodika od 1 do 20 ugljikovih atoma, skupinu heptanoil, amid, karbamat, urea, PEG, hidroksialkil škrob i polipeptid; (b) Xaa0 je odsutan, ili aminokiselina odabrana iz skupine koju čine Met i norvalin; (c) Xaa1 je odsutan ili je odabran iz skupine koju čine (S)-2-amino-5-azidopentanska kiselina, klorooctena kiselina, (S)-2-aminohept-6-enojska kiselina, 4-aminomaslačna kiselina, 5-aminopentanska kiselina, 5-aminoheksanska kiselina, ornitin, Lys, homolizin, Glu, Asp, 3-tiopropionska kiselina i Cys; (d) Xaa2 je odsutan ili je odabran iz skupine koju čine Ala, D-Ala, tertbutil-glicin, Lys, Ser, Cys i Val; (e) Xaa3 je odsutan ili je odabran iz skupine koju čine Ala, norvalin, Val i Glu; (f) Xaa4 je odsutan ili je odabran iz skupine koju čine Ala, Cys, Arg, Ser, Glu, fenilglicin i norvalin; (g) Xaa5 je odsutan ili je odabran iz skupine koju čine Tyr, Arg, Cys, Phe, N-metil-tirozin i Ala; (h) Xaa6 je odsutan ili je odabran iz skupine koju čine Glu, N-metil-glutaminska kiselina, cikloheksilglicin, Lys, Tyr, Pro, N-metil-serin, tertbutil-glicin, Val, norleucin, norvalin, 7-azatriptofan, Asn, Asp, (S)-2-aminopent-4-inska kiselina, (S)-2-aminopent-4-enska kiselina, Cys i Ala; (i) Xaa7 je odsutan ili je odabran iz skupine koju čine Asn, N-metil-asparagin, N-metil-glicin, N-metil-serin, homocistein, Thr, Tyr, fenilglicin, tert-butilglicin, alfa-metil L-asparaginska kiselina, (S)-2-amino-3-(1H-tetrazol-5-il)propanska kiselina, N-metilasparaginska kiselina, cikloleucin, 4-amino-tetrahidro-piran-4-karboksilna kiselina, Arg, Glu, Asp, Cys i Ala; (j) Xaa8 je tert-butilglicin; (k) Xaa9 je Tyr; (l) Xaa10 je 7-azatriptofan ili Trp; (m) Xaa11 je Glu; (n) Xaal2 je Tyr; (o) Xaal3 je odsutan ili je odabran iz skupine koju čine propargil-glicin, Pro, Ala, N-metil-glicin, Ser, N-metil-serin, N-metil-alanin, norvalin, Cys i Tbg; (p) Xaal4 je odsutan ili je odabran iz skupine koju čine amino izomaslačna kiselina, tert-butilglicin, Cys, Pro, Asn, fenilglicin, D-fenilglicin, N-metil-fenilglicin, norvalin, His, Ala, D-Ala, i cikloheksilglicin; (q) Xaal15 je odsutan ili je odabran iz skupine koju čine norvalin, Lys, N-ε-kaprilni lizin, N-ε-kapril lizin, N-ε-lauril lizin, N-ε-palmitoil lizin, Pro, Cys, Tyr, Gly, propargil-glicin, homoCys, N-metil-serin i tert-butilglicin; (r) Xaa16 je odsutan ili je odabran iz skupine koju čine norvalin, Cys, Lys i Ala; (s) Xaa17 je odsutan ili je odabran iz skupine koju čine Pro, Glu i Nvl; (t) Xaa18 je odsutan ili je norvalin; i (u) R2 je odsutan ili je odabran iz skupine koju čine B20, B28, K14, -NH2 i -N(CH3)2; pri čemu je polipeptid inhibitor C5; i veličina polipeptida je u rasponu od 11 do 50 aminokiselina.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time što Xaa10 je 7-azatriptofan.
3. Polipeptid prema patentnom zahtjevu 1 ili 2, naznačen time što: (i) Xaa1 je Cys ili odsutan; (ii) Xaa2 je odsutan ili je odabran iz skupine koju čine tertbutil-glicin i Val; (iii) Xaa3 je odsutan ili je odabran iz skupine koju čine Glu i Nvl; (iv) Xaa4 je odsutan ili je odabran iz skupine koju čine Arg, Cys i Ser; (v) Xaa5 je Phe ili Tyr; (vi) Xaa6 je Cys ili Glu; i/ili (vii) Xaa7 je Asp ili Asn.
4. Polipeptid prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što: (i) Xaal3 je odsutan ili je odabran iz skupine koju čine Pro, N-metil-glicin i Ala; (ii) Xaal4 je odsutan ili je odabran iz skupine koju čine cikloheksilglicin i norvalin; i/ili (iii) Xaa15 je odsutan ili je odabran iz skupine koju čine norvalin i N-metil-serin.
5. Polipeptid prema patentnom zahtjevu 1, naznačen time što sadrži premošćujući dio između dvije aminokiseline.
6. Polipeptid prema patentnom zahtjevu 5, naznačen time što premošćujući dio sadrži strukturu odabranu iz skupine koju čine strukture I-XIX; [image] pri čemu je svaki X neovisno N ili CH, tako da nijedan prsten ne sadrži više od 2 N; svaki Z je neovisno veza, NR, O, S, CH2, C(O)NR, NRC(O), S(O)vNR, NRS(O)v; svaki m je neovisno odabran od 0, 1, 2, i 3; svaki v je neovisno odabran od 1 i 2; svaki R je neovisno odabran od H i C1-C6; a svaki premošćujući dio je povezan s polipeptidom pomoću neovisno odabranih C0-C6 razmaknica.
7. Polipeptid prema patentnom zahtjevu 5, naznačen time što premošćujući dio sadrži značajku odabranu iz skupine koju čine disulfidna veza, amidna veza (laktam), tioeterska veza, aromatski prsten, nezasićeni alifatski ugljikovodični lanac, zasićeni alifatski ugljikovodični lanac i prsten triazola.
8. Polipeptid prema patentnom zahtjevu 5, naznačen time što premošćujući dio sadrži aromatski prsten koji je nastao reakcijom s poli(bromometil)benzenom.
9. Polipeptid prema patentnom zahtjevu 1, naznačen time što je navedeni polipeptid konjugiran s hidrofilnim polimerom.
10. Polipeptid prema patentnom zahtjevu 9, naznačen time što: (a) hidrofilni polimer je odabran iz skupine koju čine homopolimeri polialkilen oksida, polipropilen glikoli, polioksietilenirani polioli i njihovi kopolimeri; ili (b) hidrofilni polimer sadrži polietilen glikol (PEG).
11. Polipeptid prema patentnom zahtjevu 1, naznačen time što: (a) navedeni polipeptid sadrži najmanje jedan lipidni dio; (b) navedeni polipeptid je konjugiran s polipeptidom koji veže albumin, pri čemu polipeptid koji veže albumin sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO: 202-204; ili (c) navedeni polipeptid je konjugiran s polipeptidom koji prodire u stanicu, pri čemu polipeptid koji prodire u stanicu sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO: 205-210.
12. Pripravak, naznačen time što sadrži polipeptid prema bilo kojem od patentnih zahtjeva 1-11 i prihvatljiv nosač ili pomoćnu tvar.
13. Pripravak prema patentnom zahtjevu 12, za uporabu u postupku terapije inhibiranja cijepanja C5 u staničnom sustavu, te navedeni postupak obuhvaća dovođenje u kontakt navedenog staničnog sustava s pripravkom.
14. Pripravak za uporabu prema patentnom zahtjevu 13, naznačen time što je navedeni stanični sustav ljudski subjekt.
15. Pripravak za uporabu prema patentnom zahtjevu 14, naznačen time što navedeni ljudski subjekt sadrži bolest, poremećaj i/ili stanje povezano s komplementom, pri čemu, po izboru, navedena bolest, poremećaj i/ili stanje povezano s komplementom odabrana iz skupine koju čine upalna indikacija, rana, ozljeda, autoimuna bolest, vaskularna indikacija, neurološka indikacija, indikacija povezana s bubrezima, očna bolest, paroksizmalna noćna hemoglobinurija, i atipični hemolitički uremijski sindrom.
HRP20211561TT 2014-06-12 2015-06-12 Modulacija aktivnosti komplementa HRP20211561T8 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US201562108772P 2015-01-28 2015-01-28
EP19194070.9A EP3628680B1 (en) 2014-06-12 2015-06-12 Modulation of complement activity

Publications (2)

Publication Number Publication Date
HRP20211561T1 true HRP20211561T1 (hr) 2021-12-24
HRP20211561T8 HRP20211561T8 (hr) 2022-03-04

Family

ID=54834568

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20211561TT HRP20211561T8 (hr) 2014-06-12 2015-06-12 Modulacija aktivnosti komplementa
HRP20191763TT HRP20191763T1 (hr) 2014-06-12 2019-09-27 Modulacija komplementarne aktivnosti

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20191763TT HRP20191763T1 (hr) 2014-06-12 2019-09-27 Modulacija komplementarne aktivnosti

Country Status (26)

Country Link
US (7) US10106579B2 (hr)
EP (4) EP3973994A1 (hr)
JP (4) JP6432954B2 (hr)
KR (3) KR102346228B1 (hr)
CN (2) CN111187338A (hr)
AP (1) AP2016009612A0 (hr)
AU (3) AU2015274482B2 (hr)
BR (3) BR112016029076B1 (hr)
CA (2) CA2949985C (hr)
CY (2) CY1122227T1 (hr)
DK (2) DK3154561T3 (hr)
ES (2) ES2895029T3 (hr)
HR (2) HRP20211561T8 (hr)
HU (2) HUE045646T2 (hr)
IL (3) IL249093B (hr)
LT (2) LT3154561T (hr)
MX (2) MX2016016449A (hr)
NZ (3) NZ727420A (hr)
PL (2) PL3154561T3 (hr)
PT (2) PT3154561T (hr)
RS (2) RS59353B1 (hr)
RU (1) RU2670988C2 (hr)
SG (1) SG11201610222UA (hr)
SI (2) SI3628680T1 (hr)
WO (1) WO2015191951A2 (hr)
ZA (3) ZA201706379B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949985C (en) * 2014-06-12 2023-10-17 Ra Pharmaceuticals, Inc. Modulation of complement activity
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
KR20180094913A (ko) 2015-12-16 2018-08-24 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
US11026945B2 (en) 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
JP7301741B2 (ja) * 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
WO2019246387A1 (en) * 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
WO2020086506A1 (en) 2018-10-22 2020-04-30 Ra Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
AU2020261059A1 (en) * 2019-04-24 2021-10-14 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
CA3140193A1 (en) 2019-06-04 2020-12-10 Ra Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors
MX2022003013A (es) 2019-09-12 2022-04-07 Ra Pharmaceuticals Inc Tratamiento de enfermedades neurologicas con inhibidores del complemento.
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing
WO2024039636A1 (en) * 2022-08-16 2024-02-22 Ps Therapy, Inc. Methods of use for disulfiram and metabolites thereof

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
WO1994028424A1 (en) 1993-05-28 1994-12-08 Chiron Corporation Method for selection of biologically active peptide sequences
EP0710243B1 (en) 1993-06-29 2000-06-14 Ferring B.V. Synthesis of cyclic peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998016636A1 (fr) 1996-10-17 1998-04-23 Mitsubishi Chemical Corporation Molecule permettant d'homologuer un genotype et un phenotype, et utilisation de celle-ci
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
KR100566859B1 (ko) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Ｒｎａ-단백질 융합물을 이용한 단백질의 선별
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
JP4430235B2 (ja) 1998-08-07 2010-03-10 エミスフェアー・テクノロジーズ・インク 活性剤のデリバリーのための化合物及び組成物
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
ES2522525T3 (es) 2003-05-15 2014-11-14 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
WO2005053612A2 (en) 2003-11-26 2005-06-16 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
NZ560504A (en) 2005-01-24 2009-07-31 Pepscan Systems Bv Binding compounds, immunogenic compounds and peptidomimetics
WO2006105214A2 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
KR20080110800A (ko) 2006-03-15 2008-12-19 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
EP1876183A1 (en) * 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
WO2008109742A1 (en) 2007-03-06 2008-09-12 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
CN101679486A (zh) 2007-03-22 2010-03-24 诺瓦提斯公司 C5抗原及其用途
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
CA2680833A1 (en) 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
KR101572700B1 (ko) 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
KR20100094453A (ko) 2007-10-02 2010-08-26 포텐시아 팔마큐티칼스, 인크. 겔로부터 콤스타틴 유사체의 지속적 운반
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010014830A2 (en) 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
SG10201405377XA (en) * 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AU2009290137A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
PT2488203T (pt) 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
DK2513140T3 (en) 2009-12-16 2016-01-18 Novo Nordisk As Double-acylated GLP-1 derivatives
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011112999A2 (en) 2010-03-12 2011-09-15 The Regents Of The University Of California Lipid-peptide-polymer conjugates and nanoparticles thereof
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
PL3287142T3 (pl) 2011-04-08 2021-12-27 University Of Leicester Sposoby leczenia chorób związanych z aktywacją dopełniacza zależną od masp-2
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US20140296147A1 (en) * 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
NZ628625A (en) * 2012-02-20 2016-03-31 Swedish Orphan Biovitrum Ab Publ Polypeptides binding to human complement c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
CA2873511A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
EP3119802B1 (en) 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
CA2949985C (en) 2014-06-12 2023-10-17 Ra Pharmaceuticals, Inc. Modulation of complement activity
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
CN107427482A (zh) 2015-01-21 2017-12-01 帕西拉制药有限公司 凝血酸的多囊脂质体制剂
US9937222B2 (en) * 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
KR20180094913A (ko) 2015-12-16 2018-08-24 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3682016A4 (en) 2017-09-11 2021-06-02 RA Pharmaceuticals, Inc. FORMULATIONS FOR ADMINISTERING COMPOUNDS
KR20200095485A (ko) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
AU2020261059A1 (en) 2019-04-24 2021-10-14 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Also Published As

Publication number Publication date
PT3628680T (pt) 2021-10-07
NZ736573A (en) 2024-03-22
RS59353B1 (sr) 2019-10-31
RU2018136750A3 (hr) 2021-10-19
AU2019200828A1 (en) 2019-02-28
CY1122227T1 (el) 2020-11-25
EP4223317A3 (en) 2023-09-27
CY1124595T1 (el) 2022-07-22
IL273746B (en) 2021-03-25
ES2895029T3 (es) 2022-02-17
IL249093A0 (en) 2017-01-31
BR122023024819A2 (pt) 2023-12-26
IL249093B (en) 2020-05-31
US20190119328A1 (en) 2019-04-25
SI3628680T1 (sl) 2021-12-31
KR20170003993A (ko) 2017-01-10
CA3174909A1 (en) 2015-12-17
AU2021204313B2 (en) 2024-01-04
AU2015274482A1 (en) 2017-01-12
JP7454545B2 (ja) 2024-03-22
RU2670988C2 (ru) 2018-10-29
JP2019048834A (ja) 2019-03-28
KR20190057420A (ko) 2019-05-28
CN111187338A (zh) 2020-05-22
ZA201900497B (en) 2019-10-30
US10208089B2 (en) 2019-02-19
EP3154561A4 (en) 2018-04-18
JP6432954B2 (ja) 2018-12-05
DK3154561T3 (da) 2019-10-07
BR112016029076A8 (pt) 2022-02-08
IL273746A (en) 2020-05-31
PL3628680T3 (pl) 2022-01-10
CA2949985C (en) 2023-10-17
US11965040B2 (en) 2024-04-23
EP3973994A1 (en) 2022-03-30
LT3628680T (lt) 2021-11-25
EP3628680A1 (en) 2020-04-01
KR102503319B1 (ko) 2023-02-28
US20170137468A1 (en) 2017-05-18
SG11201610222UA (en) 2017-01-27
AU2021204313A1 (en) 2021-07-22
EP3628680B1 (en) 2021-09-08
ES2750556T3 (es) 2020-03-26
NZ727420A (en) 2018-06-29
US20200123202A1 (en) 2020-04-23
ZA201706379B (en) 2018-12-19
WO2015191951A2 (en) 2015-12-17
CA2949985A1 (en) 2015-12-17
RU2018136750A (ru) 2018-11-06
CN106456701B (zh) 2020-01-07
US10106579B2 (en) 2018-10-23
JP2020128417A (ja) 2020-08-27
WO2015191951A3 (en) 2016-03-03
JP7002597B2 (ja) 2022-02-04
RU2016147080A3 (hr) 2018-06-01
JP2017523232A (ja) 2017-08-17
PT3154561T (pt) 2019-10-25
EP3154561B1 (en) 2019-09-04
BR112016029076B1 (pt) 2024-02-15
HRP20211561T8 (hr) 2022-03-04
NZ761610A (en) 2024-03-22
BR112016029076A2 (pt) 2018-06-05
US20210246167A1 (en) 2021-08-12
US11014965B2 (en) 2021-05-25
MX2016016449A (es) 2017-08-24
KR20220002727A (ko) 2022-01-06
BR122021025449B1 (pt) 2024-02-15
HUE045646T2 (hu) 2020-01-28
HRP20191763T1 (hr) 2019-12-27
EP3154561A2 (en) 2017-04-19
US20200002380A1 (en) 2020-01-02
KR101981532B1 (ko) 2019-09-02
CN106456701A (zh) 2017-02-22
MX2021009309A (es) 2021-10-26
JP6770043B2 (ja) 2020-10-14
JP2022034057A (ja) 2022-03-02
RU2016147080A (ru) 2018-06-01
AU2015274482B2 (en) 2018-11-08
KR102346228B1 (ko) 2022-01-04
US20180371019A1 (en) 2018-12-27
AU2019200828B2 (en) 2021-04-08
SI3154561T1 (sl) 2019-11-29
US11535650B1 (en) 2022-12-27
IL281264B (en) 2022-05-01
EP4223317A2 (en) 2023-08-09
US10562934B2 (en) 2020-02-18
LT3154561T (lt) 2019-11-25
ZA202001859B (en) 2021-04-28
HUE055931T2 (hu) 2022-01-28
AP2016009612A0 (en) 2016-12-31
IL281264A (en) 2021-04-29
RS62428B1 (sr) 2021-11-30
PL3154561T3 (pl) 2019-12-31
US10435438B2 (en) 2019-10-08
DK3628680T3 (da) 2021-10-11

Similar Documents

Publication Publication Date Title
HRP20211561T1 (hr) Modulacija aktivnosti komplementa
PE20161153A1 (es) Insulina de accion prolongada y uso de la misma
AR127116A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
FR2916356B1 (fr) Nouvel agent permettant le relargage d'actifs dans des pansements contenant au moins un corps gras
PE20080709A1 (es) Polipeptidos moduladores del receptor del peptido 1 tipo glucagon (glp-1)
HRP20210057T1 (hr) Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
NZ620441A (en) Pcsk9 vaccine
ATE540054T1 (de) Antimikrobielle theta defensine und verfahren zu deren verwendung
ES2688030T3 (es) Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias
NZ708103A (en) Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2015532283A5 (hr)
AR078950A1 (es) Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales
EP2189471A4 (en) PEPTIDE FOXM1 AND MEDICINAL AGENT COMPRISING SAME
MX2015011243A (es) Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.
US20160022872A1 (en) Cell-based compositions, cell-based bandage devices and systems and methods of treatment therewith
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
RU2019126232A (ru) Пептиды и способы для лечения диабета
MX2009012742A (es) Ingrediente activo novedoso en cicatrizacion y uso del mismo.
WO2011157716A1 (en) Novel peptides for wound healing
AR073810A1 (es) Polipeptidos que tienen actividad antimicrobiana
WO2011103666A8 (en) Modulation of cytokine-induced chronic inflammatory responses